Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of “Buy” from Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has been given a consensus recommendation of “Buy” by the six brokerages that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $21.00.

ARTV has been the topic of a number of recent research reports. HC Wainwright initiated coverage on shares of Artiva Biotherapeutics in a report on Monday, December 30th. They issued a “buy” rating and a $20.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th.

Artiva Biotherapeutics Stock Up 10.7 %

Shares of ARTV stock opened at $4.44 on Tuesday. Artiva Biotherapeutics has a one year low of $3.37 and a one year high of $17.31. The company’s 50-day simple moving average is $7.92 and its 200-day simple moving average is $10.57.

Hedge Funds Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at $623,000. BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at $42,000. MetLife Investment Management LLC bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at $135,000. Acuta Capital Partners LLC bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at $680,000. Finally, RTW Investments LP bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at $2,300,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.